Fulvestrant
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fulvestrant: From Hormone Receptor-Positive Breast Cancer to HIV Infectious Disease
One-Sentence Summary
Fulvestrant is a selective estrogen receptor degrader (SERD) whose established use, as reflected throughout this evidence pack's trial and literature context, is hormone receptor-positive (HR+), HER2-negative advanced/metastatic breast cancer. The TxGNN model's top-ranked prediction for this drug is HIV infectious disease, but this direction is currently supported by 0 clinical trials and only 1 loosely related publication (which does not concern fulvestrant, HIV, or estrogen-receptor pathways directly). Evidence strength is minimal, and the model's own rationale flags this prediction as likely reflecting a spurious graph-level association rather than a clinically meaningful signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hormone receptor-positive (HR+), HER2-negative advanced/metastatic breast cancer (derived from evidence-pack context; no structured regulatory indication text was provided) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this evaluation (flagged as a High-severity data gap requiring a DrugBank lookup). Based on the evidence context surrounding this drug's other predicted indications, fulvestrant is a SERD that binds and degrades the estrogen receptor, and its efficacy in HR+/HER2- breast cancer is well established through decades of clinical use and dozens of registered trials.
There is no known pathophysiological relationship between estrogen-receptor-driven breast cancer and HIV infection. The single associated publication (PMID 40343334) is a multi-cohort omics analysis of HTLV-1-associated myelopathy — a distinct retrovirus-driven neuroinflammatory disorder — and does not mention fulvestrant, estrogen receptor biology, or HIV.
The evidence pack's own mechanistic annotation for this prediction states that the high TxGNN score likely reflects an indirect knowledge-graph connection between estrogen-receptor-related genes and viral-infection nodes, rather than a biologically or clinically meaningful link. This prediction should be treated as a hypothesis-generation artifact rather than a repurposing signal until independent pharmacological or virological evidence emerges.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40343334 | 2025 | Cohort/Omics mechanistic study (preprint) | Research Square | Multi-cohort cross-omics analysis of HTLV-1-associated myelopathy (HAM), a neglected retroviral neuroinflammatory disorder; identifies disease mechanisms and candidate therapeutic targets. Does not evaluate fulvestrant, HIV, or estrogen-receptor pathways directly. |
New Zealand Market Information
No marketing authorizations are currently registered for fulvestrant in New Zealand (0 licenses on file); the drug's status is "not marketed" in this jurisdiction.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted/hormonal therapy — selective estrogen receptor degrader (SERD), not conventional cytotoxic chemotherapy |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information. (TFDA package insert warnings/contraindications and DDI data are currently blocked by a data gap — DG001 — pending retrieval and parsing of the official package insert.)
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted association between fulvestrant and HIV infectious disease has no supporting clinical trials and only one tangentially related, non-specific publication; the evidence pack itself characterizes the underlying knowledge-graph signal as likely non-clinical. Combined with the drug's unmarketed status in New Zealand and blocked safety data, this candidate does not meet the threshold to advance past initial screening.
To proceed, the following is needed:
- TFDA/package insert warnings, contraindications, and DDI data (DG001, blocking)
- DrugBank-sourced mechanism of action detail (DG002)
- Any direct pharmacological, virological, or preclinical evidence linking estrogen-receptor degradation to HIV pathogenesis or treatment
- Re-validation of the disease-label mapping used by TxGNN, given that a lower-ranked prediction for this same drug (multiple endocrine neoplasia) was found to reflect a clear disease-ontology mismatch — the same risk should be ruled out here before further investment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.